314 related articles for article (PubMed ID: 22058081)
21. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy.
Kahaly GJ; Pitz S; Hommel G; Dittmar M
J Clin Endocrinol Metab; 2005 Sep; 90(9):5234-40. PubMed ID: 15998777
[TBL] [Abstract][Full Text] [Related]
22. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial.
Mazlumzadeh M; Hunder GG; Easley KA; Calamia KT; Matteson EL; Griffing WL; Younge BR; Weyand CM; Goronzy JJ
Arthritis Rheum; 2006 Oct; 54(10):3310-8. PubMed ID: 17009270
[TBL] [Abstract][Full Text] [Related]
23. Prospectively recorded and MedDRA-coded safety data of intravenous methylprednisolone therapy in Graves' orbitopathy.
Riedl M; Kolbe E; Kampmann E; Krämer I; Kahaly GJ
J Endocrinol Invest; 2015 Feb; 38(2):177-82. PubMed ID: 25576458
[TBL] [Abstract][Full Text] [Related]
24. Optimization of the treatment of moderate to severe and active thyroid orbitopathy considering the recommendations of the European Group on Graves' Orbitopathy (EUGOGO) [Optymalizacja leczenia umiarkowanej do ciężkiej i aktywnej orbitopatii tarczycowej z uwzględnieniem zaleceń European Group on Graves' Orbitopathy (EUGOGO)].
Nowak M; Marek B; Kos-Kudła B; Siemińska L; Londzin-Olesik M; Głogowska-Szeląg J; Nowak W; Kajdaniuk D
Endokrynol Pol; 2022; 73(4):756-777. PubMed ID: 36059167
[TBL] [Abstract][Full Text] [Related]
25. Meta-analysis of methylprednisolone pulse therapy for Graves' ophthalmopathy.
Gao G; Dai J; Qian Y; Ma F
Clin Exp Ophthalmol; 2014 Nov; 42(8):769-77. PubMed ID: 24617953
[TBL] [Abstract][Full Text] [Related]
26. Serum concentrations of HGF and IL-8 in patients with active Graves' orbitopathy before and after methylprednisolone therapy.
Nowak M; Siemińska L; Karpe J; Marek B; Kos-Kudła B; Kajdaniuk D
J Endocrinol Invest; 2016 Jan; 39(1):63-72. PubMed ID: 26062519
[TBL] [Abstract][Full Text] [Related]
27. VARIABLES AFFECTING THE LONG-TERM OUTCOME OF GRAVES ORBITOPATHY FOLLOWING HIGH-DOSE INTRAVENOUS GLUCOCORTICOID PULSE THERAPY IN PATIENTS NOT TREATED WITH ORBITAL RADIOTHERAPY.
Leo M; Mautone T; Ionni I; Profilo MA; Sabini E; Menconi F; Mazzi B; Rocchi R; Latrofa F; Nardi M; Vitti P; Marcocci C; Marinò M
Endocr Pract; 2016 Oct; 22(10):1177-1186. PubMed ID: 27732097
[TBL] [Abstract][Full Text] [Related]
28. Glucocorticoid administration for Graves' hyperthyroidism treated by radioiodine. A questionnaire survey among members of the European Thyroid Association.
Lazarus JH; Bartalena L; Marcocci C; Kahaly GJ; Krassas G; Wiersinga WM;
J Endocrinol Invest; 2010 Jun; 33(6):409-13. PubMed ID: 20101098
[TBL] [Abstract][Full Text] [Related]
29. Comparison of intravenous methylprednisolone therapy vs. oral methylprednisolone therapy in patients with Graves' ophthalmopathy.
Aktaran S; Akarsu E; Erbağci I; Araz M; Okumuş S; Kartal M
Int J Clin Pract; 2007 Jan; 61(1):45-51. PubMed ID: 16889639
[TBL] [Abstract][Full Text] [Related]
30. Comparison of efficacy and safety of parenteral versus parenteral and oral glucocorticoid therapy in Graves' orbitopathy.
Nedeljkovic Beleslin B; Ciric J; Stojkovic M; Savic S; Lalic T; Stojanovic M; Miletic M; Knezevic M; Stankovic B; Zarkovic M
Int J Clin Pract; 2020 Nov; 74(11):e13608. PubMed ID: 32649036
[TBL] [Abstract][Full Text] [Related]
31. Treatment of mild, moderate-to-severe and very severe Graves' orbitopathy.
Marcocci C; Marinò M
Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):325-37. PubMed ID: 22632369
[TBL] [Abstract][Full Text] [Related]
32. RETROSPECTIVE ANALYSIS OF PATIENTS WITH GRAVES ORBITOPATHY TREATED BY PULSES OF METHYLPREDNISOLONE, WITH A FOCUS ON ADVERSE EVENTS.
Schovanek J; Cibickova L; Karhanova M; Kovarova D; Frysak Z; Karasek D
Endocr Pract; 2018 Jul; 24(7):652-657. PubMed ID: 30048166
[TBL] [Abstract][Full Text] [Related]
33. Blood Pressure Profile and N-Terminal-proBNP Dynamics in Response to Intravenous Methylprednisolone Pulse Therapy of Severe Graves' Orbitopathy.
Miskiewicz P; Milczarek-Banach J; Bednarczuk T; Opolski G; Glowczynska R
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30261581
[TBL] [Abstract][Full Text] [Related]
34. Statins are not a risk factor for liver damage associated with intravenous glucocorticoid pulse therapy for Graves' orbitopathy.
Sabini E; Sisti E; Coco B; Leo M; Ionni I; Menconi F; Profilo MA; Mazzi B; Rocchi R; Latrofa F; Vitti P; Brunetto M; Marcocci C; Marinò M
J Endocrinol Invest; 2016 Nov; 39(11):1323-1327. PubMed ID: 27465669
[TBL] [Abstract][Full Text] [Related]
35. Systemic safety analysis of mycophenolate in Graves' orbitopathy.
Lee ACH; Riedl M; Frommer L; Diana T; Kahaly GJ
J Endocrinol Invest; 2020 Jun; 43(6):767-777. PubMed ID: 31834613
[TBL] [Abstract][Full Text] [Related]
36. Acute myocardial infarction during high-dose methylprednisolone therapy for Graves' ophthalmopathy.
Owecki M; Sowiński J
Pharm World Sci; 2006 Apr; 28(2):73-5. PubMed ID: 16791713
[TBL] [Abstract][Full Text] [Related]
37. Treatment of Graves' ophthalmopathy with high-dose intravenous methylprednisolone: a comparison of two dosing regimens.
Sánchez-Ortiga R; Moreno-Pérez O; González Sánchez V; Arias Mendoza N; Mauri Dot M; Alfayate Guerra R; López Macia A; Picó Alfonso A
Endocrinol Nutr; 2009 Mar; 56(3):118-22. PubMed ID: 19627724
[TBL] [Abstract][Full Text] [Related]
38. Safety of non-standard regimen of systemic steroid therapy in patients with Graves' orbitopathy: a single-centre experience.
Sawicka-Gutaj N; Gruszczyński D; Zawalna N; Nijakowski K; Skiba A; Pochylski M; Sowiński J; Ruchała M
Pharmacol Rep; 2024 Feb; 76(1):185-194. PubMed ID: 38273183
[TBL] [Abstract][Full Text] [Related]
39. Circulating microRNA predicts insensitivity to glucocorticoid therapy in Graves' ophthalmopathy.
Shen L; Huang F; Ye L; Zhu W; Zhang X; Wang S; Wang W; Ning G
Endocrine; 2015 Jun; 49(2):445-56. PubMed ID: 25588771
[TBL] [Abstract][Full Text] [Related]
40. Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent graves' orbitopathy: a retrospective cohort study.
Lai A; Sassi L; Compri E; Marino F; Sivelli P; Piantanida E; Tanda ML; Bartalena L
J Clin Endocrinol Metab; 2010 Mar; 95(3):1333-7. PubMed ID: 20061414
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
